Melatonin Analog PD6735 and Anxiety

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$275,845.00
Award Year:
2006
Program:
SBIR
Phase:
Phase I
Contract:
1R43MH077349-01
Award Id:
79875
Agency Tracking Number:
MH077349
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
P2D, INC., 3130 HIGHLAND AVE, 3RD FL, CINCINNATI, OH, 45219
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
FRANK ZEMLAN
(513) 475-6618
fzemlan@p2dinc.com
Business Contact:
JAMES MULCHAHEY
(513) 475-6618
JMULCHAHEY@P2DINC.COM
Research Institution:
n/a
Abstract
DESCRIPTION (Provided by applicant): P2D, Inc. is developing a synthetic melatonin analog, PD6735, for the treatment of anxiety. Preliminary Studies suggest that PD6735 reduces anxiety in rodents. Additional pre-clinical studies indicate that PD6735 is safe and is a high-affinity melatonin agonist at MT1 and MT2 receptors. The goal of this Phase 1 SBIR proposal is to determine PD6735 efficacy in pre-clinical rodent models of anxiety. Preliminary Studies indicate that PD6735 significantly affects open field behaviors associated with anxiety: freezing (immobility) and rearing. Immobility and rearing are thought to be anxiety-related measures which are responsive to clinically effective anti-anxiety drugs (anxiolytics). We propose to extend our Preliminary Studies and perform more detailed PD6735 dose-response and time-course studies employing the open field test as well as two other anxiolytic screening tests: 1) the elevated plus maze, and 2) defensive prod-burying. Immediately after behavioral testing PD6735 plasma and brain levels will be assayed to determine the relationship between PD6735 levels and PD6735's anxiolytic effects. As PD6735 is already in clinical development, it can be evaluated relatively rapidly as an anxiolytic in humans should pre-clinical efficacy studies be positive. The Specific Aims of our Phase 1 study are: Specific Aim 1: Determine the time course of the anti-anxiety effect of acute PD6735 in the rodent open field test employing melatonin and diazepam as controls. Specific Aim 2: Measure plasma and brain PD6735 levels in Specific Aim 1 animals immediately after behavioral testing and determine the relationship between anxiety measures and plasma/brain PD6735 levels. Specific Aim 3: Determine the time course of the anti-anxiety effect of acute PD6735 in the rodent elevated plus maze model of anxiety employing melatonin and diazepam as controls. Further, measure plasma and brain PD6735 levels immediately after behavioral testing and determine the relationship between anxiety measures and plasma/brain PD6735 levels. Specific Aim 4: Determine the time course of the anti-anxiety effect of acute PD6735 in the rodent defensive prod-burying model of anxiety employing melatonin and diazepam as controls. Further, measure plasma and brain PD6735 levels immediately after behavioral testing and determine the relationship between anxiety measures and plasma/brain PD6735 levels.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government